135 related articles for article (PubMed ID: 16189442)
1. Treatment with oral etoposide for childhood recurrent ependymomas.
Sandri A; Massimino M; Mastrodicasa L; Sardi N; Bertin D; Basso ME; Todisco L; Paglino A; Perilongo G; Genitori L; Valentini L; Ricardi U; Gandola L; Giangaspero F; Madon E
J Pediatr Hematol Oncol; 2005 Sep; 27(9):486-90. PubMed ID: 16189442
[TBL] [Abstract][Full Text] [Related]
2. Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide.
Chamberlain MC
Pediatr Neurol; 2001 Feb; 24(2):117-21. PubMed ID: 11275460
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy for recurrent spinal cord ependymona.
Chamberlain MC
Cancer; 2002 Sep; 95(5):997-1002. PubMed ID: 12209682
[TBL] [Abstract][Full Text] [Related]
4. Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.
Jakacki RI; Foley MA; Horan J; Wang J; Kieran MW; Bowers DC; Bouffet E; Zacharoulis S; Gill SC
J Neurooncol; 2016 Aug; 129(1):131-8. PubMed ID: 27287856
[TBL] [Abstract][Full Text] [Related]
5. No responses to oral etoposide in 15 patients with recurrent brain tumors.
Korones DN; Fisher PG; Cohen KJ; Dubowy RL
Med Pediatr Oncol; 2000 Jul; 35(1):80-2. PubMed ID: 10881014
[No Abstract] [Full Text] [Related]
6. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors.
Needle MN; Molloy PT; Geyer JR; Herman-Liu A; Belasco JB; Goldwein JW; Sutton L; Phillips PC
Med Pediatr Oncol; 1997 Jul; 29(1):28-32. PubMed ID: 9142202
[TBL] [Abstract][Full Text] [Related]
7. Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group.
Mason WP; Goldman S; Yates AJ; Boyett J; Li H; Finlay JL
J Neurooncol; 1998 Apr; 37(2):135-43. PubMed ID: 9524092
[TBL] [Abstract][Full Text] [Related]
8. Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
Schiavetti A; Varrasso G; Maurizi P; Cappelli C; Clerico A; Properzi E; Castello MA
J Pediatr Hematol Oncol; 2000; 22(2):119-24. PubMed ID: 10779024
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Rudà R; Bosa C; Magistrello M; Franchino F; Pellerino A; Fiano V; Trevisan M; Cassoni P; Soffietti R
Neuro Oncol; 2016 Feb; 18(2):261-8. PubMed ID: 26323606
[TBL] [Abstract][Full Text] [Related]
10. Response of recurrent medulloblastoma to low-dose oral etoposide.
Ashley DM; Meier L; Kerby T; Zalduondo FM; Friedman HS; Gajjar A; Kun L; Duffner PK; Smith S; Longee D
J Clin Oncol; 1996 Jun; 14(6):1922-7. PubMed ID: 8656261
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Korones DN; Smith A; Foreman N; Bouffet E
Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
[TBL] [Abstract][Full Text] [Related]
12. Oral etoposide in relapsed or refractory Ewing sarcoma: a monoinstitutional experience in children and adolescents.
Podda MG; Luksch R; Puma N; Gandola L; Morosi C; Terenziani M; Ferrari A; Casanova M; Spreafico F; Meazza C; Catania S; Schiavello E; Biassoni V; Chiaravalli S; Massimino M
Tumori; 2016; 102(1):84-8. PubMed ID: 26797935
[TBL] [Abstract][Full Text] [Related]
13. Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma.
Sardi I; Sanzo M; Giordano F; Sandri A; Mussa F; Donati PA; Genitori L
Oncol Rep; 2008 May; 19(5):1219-23. PubMed ID: 18425379
[TBL] [Abstract][Full Text] [Related]
14. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
15. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
16. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.
Grill J; Le Deley MC; Gambarelli D; Raquin MA; Couanet D; Pierre-Kahn A; Habrand JL; Doz F; Frappaz D; Gentet JC; Edan C; Chastagner P; Kalifa C;
J Clin Oncol; 2001 Mar; 19(5):1288-96. PubMed ID: 11230470
[TBL] [Abstract][Full Text] [Related]
17. Oral etoposide for refractory and relapsed neuroblastoma.
Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 1999 Oct; 17(10):3221-5. PubMed ID: 10506622
[TBL] [Abstract][Full Text] [Related]
18. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
[TBL] [Abstract][Full Text] [Related]
19. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study.
Ashby LS; Shapiro WR
J Neurooncol; 2001 Jan; 51(1):67-86. PubMed ID: 11349883
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
